Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma

ONCOLOGY

Volumn 15, Issue 3 SUPPL. 5, 2001, Pages 52-54

  Ajani, Jaffer A ^a   Baker, Jackie ^a   Pisters, Peter W ^a   Ho, Linus ^a   Feig, Barry ^a   Mansfield, Paul F ^b  

^a Department of Medicine ^*

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN;

DRUG EFFECT; ESOPHAGUS TUMOR; HUMAN; LOWER ESOPHAGUS SPHINCTER; REVIEW; STOMACH TUMOR;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMAN; STOMACH NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0035289195     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Greenlee RT, Hill-Harman MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001.
2. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993.
3. Pyrhonen S, Kuitunen T, Kouri M: A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer (abstract). Ann Oncol 3(suppl):12, 1992.
4. Glimelius B, Hoffmann K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189-190, 1994.
5. Scheithauer W, Komek G, Zeh B, et al: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial (abstract), p 68. Proceedings of Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, Koln, Germany, 1995.
6. Kambe M, Wakui A, Nakao I, et al: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers (abstract 584). Proc Am Soc Clin Oncol 12:198, 1993.
7. Kohne CH, Thuss-Patience N, Catane R, et al: Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer (abstract 993). Proc Am Soc Clin Oncol 18:258, 1999.
8. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989.
9. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997.
10. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-23, 1999.
11. Saltz LB, Spriggs D, Schaaf LJ, et al: Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 16:3858-3865, 1998.
12. Ilson DH, Saltz L, Enzinger P, et al: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270-3275, 1999.